Cardiovascular risks associated with clarithromycin

BMJ (Online)

Volumn 352, Issue , 2016, Pages

  Iyer, Geetha ^a   Alexander, G Caleb ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTIINFECTIVE AGENT; AZITHROMYCIN; CLARITHROMYCIN; ERYTHROMYCIN; METRONIDAZOLE; PENICILLIN V; PLACEBO; PROTON PUMP INHIBITOR;

CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CLINICAL DECISION MAKING; CLINICAL PRACTICE; DRUG USE; EDITORIAL; HEART ARRHYTHMIA; HEART INFARCTION; HELICOBACTER INFECTION; HUMAN; MORTALITY; PRIORITY JOURNAL; QT PROLONGATION; STATISTICAL ANALYSIS; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED; DRUG EFFECTS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; RESPIRATORY TRACT INFECTIONS;

AMOXICILLIN; ANTI-BACTERIAL AGENTS; CARDIOVASCULAR DISEASES; CLARITHROMYCIN; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; RESPIRATORY TRACT INFECTIONS;

EID: 84959422344     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.i23     Document Type: Editorial

References (10)

1. Guelon D, Bedock B, Chartier C, Haberer JP. QT prolongation and recurrent "torsades de pointes" during erythromycin lactobionate infusion. Am J Cardiol 1986;58: 666. doi:10.1016/0002-9149(86)90306-1 3751946
2. Albert RK, Schuller JLCOPD Clinical Research Network. Macrolide antibiotics and the risk of cardiac arrhythmias. Am J Respir Crit Care Med 2014;189: 1173-80. doi:10.1164/rccm.201402-0385CI 24707986
3. Ray WA, Murray KT, Hall K, Arbogast PG, Stein CM. Azithromycin and the risk of cardiovascular death. N Engl J Med 2012;366: 1881-90. doi:10.1056/NEJMoa1003833 22591294
4. Svanström H, Pasternak B, Hviid A. Use of clarithromycin and roxithromycin and risk of cardiac death: cohort study. BMJ 2014;349: g4930. doi:10.1136/bmj.g4930 25139799
5. Winkel P, Hilden J, Hansen JF et al. CLARICOR trial group. Clarithromycin for stable coronary heart disease increases all-cause and cardiovascular mortality and cerebrovascular morbidity over 10 years in the CLARICOR randomised, blinded clinical trial. Int J Cardiol 2015;182: 459-65. doi:10.1016/j.ijcard.2015.01.020 25602299
6. Wong AYS, Root A, Douglas I et al. Cardiovascular outcomes associated with use of clarithromycin: population based study. BMJ 2016;352: h6926.
7. Whitaker HJ, Farrington CP, Spiessens B, Musonda P. Tutorial in biostatistics: the self-controlled case series method. Stat Med 2006;25: 1768-97. doi:10.1002/sim.2302 16220518
8. Schembri S, Williamson PA, Short PM et al. Cardiovascular events after clarithromycin use in lower respiratory tract infections: analysis of two prospective cohort studies. BMJ 2013;346: f1235. doi:10.1136/bmj.f1235 23525864
9. Shapiro DJ, Hicks LA, Pavia AT, Hersh AL. Antibiotic prescribing for adults in ambulatory care in the USA, 2007-09. J Antimicrob Chemother 2014;69: 234-40. doi:10.1093/jac/dkt301 23887867
10. Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2013. www.cdc.gov/drugresistance/threat-report-2013/pdf/ar-threats-2013-508.pdf.